{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76.55","upperLimit":"93.32","value":"86.49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Binomial estimate of the 3-year PFS rate defined as \"Yes\" for patients who were followed up per protocol and were progression free at 3-years, and \"No\" for those who either experienced a progression or were lost to follow-up/withdrew from the trial within 3 years from initiation of treatment. Progression was determined by MRI using the COG Guidelines for Measurement of Tumor Size (\\>25% increase in 2D or \\>40% in 3D of the product of perpendicular diameters of the target lesion) as well as by tumor marker assessments which were mandatory for this study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive induction therapy comprising carboplatin IV over 15-60 minutes on day 1 and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CR or continued CR (CCR) undergo 3DRT or IMRT QD 5 days a week for 4 weeks. Patients with normalization of markers who fail to achieve CR or PR are strongly recommended to undergo second-look surgery. Patients found to have fibrosis, scar, mature teratoma, or non-viable tumor undergo 3DRT or IMRT QD 5 days a week for 4 weeks. Patients with stable disease (SD) or PR with \\> 0.5 cm (suprasellar) or \\> 1 cm (pineal) but =\\< 1.5 cm residual disease do not undergo second-look surgery and undergo 3DRT or IMRT QD 5 days a week for 4 weeks.","id":"OG000","title":"Stratum 2 Localized Germinoma"}],"paramType":"NUMBER","populationDescription":"Localized CNS Germinoma treated with dose-reduced RT (18 Gy WVI + 12 Gy primary site boost) and had complete response (CR) after induction chemotherapy by MRI and tumor marker criteria; or underwent second-look surgery and were found to have mature teratoma, residual scar or fibrosis and fit the definition of CR after second-look surgery.","reportingStatus":"POSTED","timeFrame":"3 years","title":"3-year PFS Rate of Patients With Localized CNS Germinoma Who Were Treated With Reduced Dose Radiation Therapy","type":"PRIMARY","unitOfMeasure":"percentage of patients"}